Vaccine Info

JYNNEOS Smallpox (Monkeypox) Vaccine

Authored by
Last reviewed
June 25, 2022

JYNNEOS® (MVA-BN) Smallpox (Monkeypox) Vaccine Description 2022

Bavarian Nordic JYNNEOS smallpox (Monkeypox) vaccine is based on a live, attenuated vaccinia virus, Modified Vaccinia Ankara (MVA), incapable of replicating in the human body yet able to elicit a potent immune response. The MVA is cultured in Chicken Embryo Fibroblast cells and a serum-free medium. It is purified and filtered from the cells using various methods, including benzonase digestion.

The two-dose MVA-BN (JYNNEOS®, USA, MVANEX®, Europe; IMVAMUNE®, Canada) was Approved in 2019 by the U.S. Food and Drug Administration (FDA) and by the European Medicines Agency EMEA/H/C/002596 in 2013 and is indicated for preventing smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for infection. JYNNEOS is the only FDA-approved non-replicating smallpox and monkeypox vaccine for non-military use. In November 2021, the U.S. CDC's vaccine committee unanimously voted for JYNNEOS as an alternative to ACAM2000 for primary vaccination and booster doses. 

Jynneos vaccine was developed in partnership with the U.S. Government to ensure adult populations can be protected from smallpox/monkeypox, including people with weakened immune systems or at high risk of adverse reactions to traditional smallpox vaccines based on replicating vaccinia virus strains. In terms of efficacy, MVA-BN induces strong cellular activity and humoral (antibody) immune response and has demonstrated an ability to stimulate a response even in individuals with pre-existing immunity against vaccinia. In 2020, positive topline results from a Phase 3 lot-consistency trial of the freeze-dried formulation of MVA-BN were reported. The three lots induced equivalent antibody responses, meeting the study's primary endpoint, while the favorable safety profile was in line with the cumulative safety experience of the approved liquid-frozen formulation.

On June 21, 2021, the U.S. FDA updated JYNNEOS - STN: BL 125678/20. The Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) vaccine is marketed under the brand names IMVANEX in the European Union and IMVAMUNE in Canada

Bavarian Nordic is headquartered in Kvistgaard, Denmark (OTCMKTS: BVNRY) (OMX: BAVA), focused on developing, manufacturing, and commercializing life-saving vaccines.

JYNNEOS Availability

As of June 25, 2022, the MVA-BN (Jynneos, IMVANEX, MVAMUNE) vaccine was available in Canada, CyprusDenmarkEuropeFrance, Germany, Isreal,  Nigeria, Portugal, ScotlandSpain, the USA, and the U.K. The BerlinLondon, MadridMontreal, New York City, and Toronto Public Health departments offer MVA-BN vaccines to protect residents from the monkeypox virus outbreak. In addition, a subset of persons at occupational risk for exposure to orthopoxvirus infections and certain U.S. military personnel are offered Jynneos. In the U.K., the Vaccination Act of 1853 made it compulsory for all children born after August 1953 to be vaccinated against smallpox during their first three months of life. And on June 21, 2022, the U.K. expanded access to Imvanex.


JYNNEOS (MVA-BN) Vaccine (IMVANEX, IMVAMUNE) utilizes Chicken Embryo Fibroblast cells to produce the vaccine. Replication-competent poxvirus strains can cause clinical infection in humans as well as produce an infectious virus that can be transmitted to others. However, replication-deficient poxvirus strains, including modified vaccinia Ankara (MVA), do not produce infectious viruses in humans and therefore do not cause clinical infection. As such, replication-deficient poxvirus strains pose a substantially lower risk of adverse events compared with replication-competent strains. 

JYNNEOS Indication

JYNNEOS is indicated to protect people from smallpox and monkeypox viruses, including people with weakened immune systems or at high risk of adverse reactions to traditional smallpox vaccines based on replicating vaccinia virus strains. JYNNEOS involves a replication-deficient virus. The WHO says 'Monkeypox is a sylvatic zoonosis caused by the monkeypox virus and belongs to the Orthopoxvirus family, including variola virus (smallpox). Human monkeypox (hMPXV) is a zoonotic viral disease caused by the Monkeypox virus

On June 21, 2022, the UKHSA published its vaccine strategy in response to the monkeypox outbreak. As monkeypox is related to the virus which causes smallpox, vaccines developed for smallpox are considered to provide cross-protection against monkeypox. Therefore, the Joint Committee on Vaccination and Immunisation proposed that vaccination should be offered as soon as feasible to GBMSM at the highest risk due to a large number of contacts. However, there is very limited evidence on whether MVA-BN can prevent or modify disease when given to contacts after possible exposure to the monkeypox virus.

The WHO states, 'Vaccination against smallpox with first-generation vaccinia-virus-based smallpox vaccine was 85% effective in preventing monkeypox in the past. When properly administered before exposure to monkeypox, vaccines effectively protect people against monkeypox.' Therefore, persons exposed to the monkeypox virus and who have not received the smallpox vaccine within the last three years should consider getting vaccinated. The sooner the person receives the vaccine, the more effective it will be in protecting against the monkeypox virus, says the CDC. 

JYNNEOS U.S. CDC Presentations

On June 23, 2022, the U.S. CDC Advisory Committee on Immunization Practices (ACIP) meeting reviewed presentations focused on the 2022 monkeypox virus disease outbreaks and medical monkeypox vaccines and treatment countermeasures led by Captian Brett W. Petersen, MD, MPH.

The U.S. CDC issued Health Alert Network CDCHAN-00468 on June 14, 2022 - Updated Case-finding Guidance: Monkeypox Outbreak—U.S. On May 27, 2022, the U.S. CDC's Morbidity and Mortality Weekly Report published - Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices — U.S., 2022. Potential vaccinees should weigh the risks and benefits of each vaccine when deciding which to receive. On April 8, 2022, a CDC MMWR reviewed: Monkeypox in a Traveler Returning from Nigeria — Dallas, Texas, July 2021.

During the U.S. CDC's ACIP Meeting on September 29, 2021, Agam Rao, M.D. CAPT, U.S. Public Health Service, presented: Background information to interpret GRADE tables and Evidence to Recommendations framework about the JYNNEOS vaccine. The Demographic Subgroup Information - JYNNEOS. On November 3, 2021, Pablo Sanchez, MD Chair, ACIP Orthopoxvirus W.G., led an update discussion, followed by Brett Petersen, MD, MPH, who presented Clinical Guidance for the use of JYNNEOS. Then, Agam Rao, MD CAPT, presented a Summary of Evidence to Recommendations Frameworks for Using JYNNEOS.


JYNNEOS is for subcutaneous injection only. Administer 2-doses (0.5 mL each) 28 days apart. JYNNEOS is administered as a live virus that is non-replicating. People who receive JYNNEOS are not considered vaccinated until they receive both vaccine doses. Full protection is not conferred until two weeks after receipt of the second dose. However, robust antibody response following a single dose of JYNNEOS has been observed in clinical trials.


The CDC stated regarding booster doses, the systematic review identified one randomized controlled trial and 17 observational studies that included a total of 6,417 subjects. After considering geometric mean titer and seroconversion rate together, the Work Group estimated with very low (level 4) certainty that a small increase in disease prevention occurs after the JYNNEOS booster versus the JYNNEOS primary series only. The ACIP unanimously voted in favor of recommending JYNNEOS boosters as an alternative to ACAM2000 boosters in persons who received ACAM2000 as the primary vaccine.

JYNNEOS Side Effects

This smallpox/monkeypox vaccine is not recommended for the general public in the USA since smallpox has been eradicated. According to the U.S. CDC, routine smallpox vaccination among the American public stopped in 1972. However, health officials are prepared to use a vaccine if there were a smallpox outbreak, says the CDC. And there is no visible "take" and, as a result, no risk for spread to other parts of the body or other people. In addition, a major advantage of MVA-BN is the virus' inability to replicate in a vaccinated individual, unlike the original smallpox vaccines. 

Typical severe adverse reactions known for replicating vaccinia virus strains, such as myocarditis, encephalitis, generalized vaccinia, or eczema vaccinatum, were not observed during Jynneos's clinical development program. The U.S. FDA reports in smallpox vaccine-naïve healthy adults, the most common (> 10%) solicited injection site reactions were pain (84.9%), redness (60.8%), swelling (51.6%), induration (45.4%), and itching (43.1%); the most common solicited systemic adverse reactions were muscle pain (42.8%), headache (34.8%), fatigue (30.4%), nausea (17.3%) and chills (10.4%).

To report SUSPECTED ADVERSE REACTIONS, contact Bavarian Nordic at the toll-free phone at 1-800-675-9596 or VAERS, a passive reporting system, meaning it relies on individuals to send in reports of their experiences. Anyone can submit a report to VAERS, including parents and patients. Healthcare providers are required by law to report to VAERS.

JYNNEOS Contraindication

JYNNEOS is contraindicated in persons with a serious allergy to a vaccine component, says the CDC.

JYNNEOS U.S. Government Contracts

On June 10, 2022, Bavarian announced the U.S. BARDA had ordered an additional 500,000 doses of liquid-frozen JYNNEOS for delivery in 2022. With the previous order from BARDA for 1.4 million doses of liquid-frozen JYNNEOS, awarded in 2020, this order will bring the total U.S. inventory of the vaccine to nearly 2 million doses.

On June 6, 2022, Dawn O'Co​nnell, U.S. HHS Assistant Secretary for Preparedness and Response (ASPR), wrote: 'We have been preparing (vaccines) for moments like this through the ongoing work of the BARDA and the SNS.' 

On May 18, 2022, Bavarian Nordic announced today that BARDA exercised the first options (119 million doses) under the contract to supply a freeze-dried version of the JYNNEOS smallpox vaccine. The transfer of the freeze-drying process to our new fill and finish plant in Kvistgaard was initiated last year and, following an FDA inspection in 2022, will lead to commercial manufacturing in 2023. To date, the Company has supplied nearly 30 million doses of the liquid-frozen version to HHS, with the vast majority being delivered for emergency use before approval of the vaccine by the FDA in 2019. The FDA also granted Bavarian Nordic a Priority Review Voucher under the Material Threat Medical Countermeasure program. 

Since 2010, Bavarian Nordic has manufactured its liquid-frozen MVA-BN smallpox vaccine and has supplied 28 million doses to the U.S. Strategic National Stockpile (SNS) for emergency use. The ten-year contract, awarded in 2017, also includes pricing for additional orders of vaccine bulk and vaccine doses of either liquid-frozen or freeze-dried MVA-BN. On April 30, 2020, the Company confirmed a contract expansion that covers two years of performance and includes manufacturing additional bulk vaccines and supplying up to 1.4 million doses of liquid frozen JYNNEOS. This is the first order from the U.S. following the approval of JYNNEOS by the FDA in September 2019, which will ensure the availability of a smallpox vaccine in the U.S. Strategic National Stockpile for potential use by first-line responders.

Monkeypox Outbreak 2022

As of June 25, 2022, about (70) countries had reported about 4,201 probable monkeypox virus patients since early May 2022. And in the USA, the CDC recently reported that (24) states and the District of Columbia had confirmed (201) monkeypox-infected patients.

JYNNEOS News 2019 - 2022

June 23, 2022 - New York City's health department announced 'that (Jynneos) vaccination is available for people who may have been recently exposed to monkeypox.'

June 21, 2022 - A strategy published by the UKHSA recommends that men at higher risk of monkeypox exposure should be offered vaccines to help control the recent outbreak.

June 20, 2022 - The New Jersey Department of Health announced the first probable case of monkeypox in a North Jersey individual on June 18.

June 14, 2022 - Bavarian Nordic A/S announced the European Health Emergency Preparedness and Response Authority (HERA) had ordered 110,000 MVA-BN vaccine doses, which will be made available to E.U. Member States, and Norway and Iceland. Deliveries to HERA are scheduled to be completed during the following months.

June 10, 2022 - Paul Chaplin, President, and CEO of Bavarian Nordic, said in a press release, "The long-term commitment from the U.S. government to the development and procurement of JYNNEOS has provided the opportunity to act swiftly, ensuring rapid deployment of vaccines to mitigate the current monkeypox outbreak."

June 9, 2022 - Germany's Standing Committee on Vaccination (STIKO) recommended Imvanex vaccine become available to people exposed to the MPXV in the last 14 days.

June 7, 2022 - Bavarian Nordic A/S announced that the Public Health Agency of Canada would purchase the IMVAMUNE® smallpox vaccine at approximately USD 56 million. Deliveries under this new five-year contract are expected to occur from 2023. In parallel, Bavarian Nordic continues to secure contracts with other countries, including Denmark.

June 6, 2022 - CNBC reported the U.S. has more than 36,000 doses of the Jynneos monkeypox vaccine immediately available in the strategic national stockpile.

June 1, 2022 - Healthcare workers in the UK will be offered MPXV vaccines as the government buys 20,000 doses.

May 30, 2022 - Bavarian Nordic A/S announced today the signing of a number of supply contracts with undisclosed countries for the Company's monkeypox/smallpox vaccine. As a consequence of these orders, the Company raised its expectations for the financial results for 2022, with revenue now expected to be between DKK 1,400 and 1,600 million (previously between DKK 1,300 and 1,500 million).

May 27, 2022 - The U.S. CDC published an extensive Jynneos overview.

May 27, 2022 - The U.K. purchased over 20,000 doses of Imvanex (Jynneos).

May 26, 2022 - Denmark confirmed about 200 monkeypox vaccines arrived from the Netherlands and intends to purchase thousands.

May 25, 2022 - Bavarian Nordic A/S announced the signing of a supply contract with an undisclosed country for the Company's smallpox vaccine. While the terms of the agreement remain undisclosed, the order will positively impact the Company's financial guidance for 2022, with revenue now expected to be between DKK 1,300 and 1,500 million (previously between DKK 1,100 and 1,400 million).

May 25, 2022 - Al-Rai daily reported the Ministry of Health intends to purchase 5,000 doses of smallpox (monkeypox) vaccines.

May 25, 2022 - CNN reported the Jynneos vaccine was offered to healthcare staff in Boston, MA.

May 24, 2022 - The Canadian government announced it had deployed the Imvamune vaccine in Quebec.

May 24, 2022 - Reuters reported Germany's health minister confirmed an order for 40,000 smallpox/monkeypox vaccine doses from Bavarian Nordic.

May 23, 2022 - CNN reported '"I can report that there has been a request for release of the Jynneos vaccine from the National Stockpile for some of the high-risk contacts of some of the early patients, so that is actively happening right now," Dr. Jennifer McQuiston, deputy director of the Division of High Consequence Pathogens and Pathology within the CDC. "Right now, we have over 1,000 doses of that available."

May 23, 2022 - The U.K. health agency confirmed vaccinations of high-risk contacts of monkeypox cases are ongoing. Over 1,000 doses of Imvanex have been issued to NHS Trusts, with about 3,500 doses of Imvanex remaining in the U.K.

May 23, 2022 - The WSJ reported  Bavarian Nordic is producing additional smallpox vaccine inventory as governments seek to purchase doses related to the monkeypox outbreak.

May 19, 2022 - The Company announced it secured a contract with an undisclosed European country to supply its IMVANEX® (Jynneos) smallpox/monkeypox vaccine. This order has no impact on the Company's financial guidance for 2022.

May 18, 2022 - The WHO confirmed monkeypox vaccinations (MVA-BN, Jynneos) are being offered to higher-risk contacts in England.

May 18, 2022 - Paul Chaplin, President, and CEO of Bavarian Nordic stated, "We are pleased to announce the exercise of the first options under our contract with the U.S. government to deliver a freeze-dried version of the smallpox vaccine with an improved shelf-life, which will be manufactured at our new fill and finish facility."

May 14, 2022 - Two additional individuals have been diagnosed with monkeypox in London.

May 12, 2022 - Portugal confirmed five cases of monkeypox.

May 7, 2022 - The U.K. Health Security Agency confirmed an individual has been diagnosed with monkeypox in England following travel to Nigeria. People without symptoms are not considered infectious but, as a precaution, those who have been in close proximity to this traveler are being contacted to ensure that if they do become unwell they can be treated quickly. 

March 2, 2022 - SIGA Technologies, Inc. announced that it had initiated the clinical program to support a U.S. FDA label expansion for Post-Exposure Prophylaxis for oral TPOXX®, approved in July 2018 for the treatment of smallpox. The first study compares the enrolled participants' immune response to the Jynneos smallpox vaccines compared with the immune response to Jynneos while on TPOXX treatment. 

February 11, 2022 - PLOS published an Original Research study: The changing epidemiology of human monkeypox—A potential threat? A systematic review. 'Overall, monkeypox is gradually evolving to become of global relevance. Surveillance and detection programs are essential tools for understanding the continuously changing epidemiology of this resurging disease.'

November 18, 2021 - Laboratory testing at the Centers for Disease Control and Prevention showed that recently discovered vials marked as "smallpox" contain vaccinia, the virus used in the smallpox vaccine. There is no evidence that the vials contain the variola virus, the cause of smallpox. Revenue in the third quarter totaled DKK 449 million comprised of DKK 214 million from sales of MVA-BN smallpox vaccine.

November 16, 2021 - The Maryland Department of Health, in collaboration with the U.S. CDC, confirmed a single case of monkeypox virus infection in a Maryland resident who recently returned from Nigeria. The individual is currently recovering in isolation and is not hospitalized. Therefore, no special precautions are recommended at this time for the general public.

November 12, 2021 - Bavarian Nordic A/S announced today its interim financial results for the first nine months of 2021 and business progress for the third quarter of 2021.

November 4, 2021 - Mr. Bill Gates, founder of Microsoft in a meeting with Jeremy Hunt, chair of the U.K. Health Select Committee, warned of future pandemics as well as smallpox terror attacks.

September 30, 2021 - The U.S. CDC issued a Travel Alert regarding the Monkeypox outbreak in the Democratic Republic of the Congo. People infected with monkeypox can spread the virus to others through the air when they cough, sneeze or talk. In addition, the body fluids and skin sores of a person infected with monkeypox are also infectious.

September 15, 2021 - Guinea declared the end of the Marburg virus disease outbreak having recorded no new cases over the past 42 days, two incubation periods, or the time between infection and the onset of symptoms. The virus was confirmed on 9 August, marking the first time the disease emerged in the country and in West Africa. Only one case—the index patient who was diagnosed with the virus posthumously—was recorded and more than 170 high-risk contacts were monitored for 21 days. 

September 12, 2021 - The WHO reported nine suspected monkeypox cases were reported in Nigeria in August 2021, which was a substantial increase from the previous month. Overall, seventy-nine suspected cases have been reported this year with no deaths recorded. In mid-July 2021, a case of monkeypox from Nigeria was reported to have been imported into the United States highlighting the risk of cross-border spread and the need for collaboration to disease management and response.

July 16, 2021 - The Centers for Disease Control and Prevention and the Texas Department of State Health Services confirmed a case of human monkeypox in a U.S. resident who recently traveled from Nigeria to the U.S.

June 24, 2021 - Local media reported Public Health Wales and Public Health England have confirmed they are monitoring three cases of imported monkeypox identified in North Wales.

June 11, 2021 - Bavarian Nordic A/S announced the Company was recently engaged by Public Health England (PHE) and the Medicines and Health Products Regulatory Agency (MHRA) to supply its IMVANEX® smallpox vaccine in response to new cases of monkeypox in the U.K. Two related cases were confirmed and admitted to a hospital in Liverpool, England. Bavarian Nordic previously delivered IMVANEX to PHE in connection with the first human cases of monkeypox in the U.K. in 2018 and later in 2019, when several unrelated human cases were imported from Nigeria with subsequent infection of a healthcare worker in the U.K. The U.S. trade name is JYNNEOS.

June 9, 2021 - Public Health Wales confirmed it is monitoring two cases of imported monkeypox after their discovery in north Wales.

May 25, 2021 - The United Kingdom and Northern Ireland notified the WHO of one laboratory-confirmed case of monkeypox. The patient arrived in the United Kingdom on 8 May 2021. Before travel, the patient had lived and worked in Delta State, Nigeria.

May 7, 2021 - Bavarian Nordic A/S announced today that the U.S. Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response, has exercised the final $12 million option under the $202 million order for JYNNEOS awarded in April 2020. This project has been supported in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201700019C.

March 22, 2021 - Bavarian Nordic A/S announced that the Public Health Agency of Canada had ordered the IMVAMUNE® smallpox vaccine to the national stockpile at a total value of $31.2 million. Deliveries of the vaccines are expected to occur from the first quarter of 2022, with anticipated completion in 2023. Hence this order, made under an existing contract with PHAC, will have no impact on the Company's financial guidance for 2021.    

December 16, 2020 - Bavarian Nordic A/S announced the U.S. BARDA exercised an option covering the majority of the second year of performance under the USD 200 million order for JYNNEOS awarded in April 2020. The first USD 106 million covered both manufacturings of bulk vaccine and supply of liquid-frozen JYNNEOS doses and was secured upon contract award last April. BARDA is committing to an additional USD 83 million with the current option to procure more bulk smallpox vaccines manufactured and invoiced in 2021. The last option of the order, amounting to USD 12 million, is to supply additional liquid-frozen JYNNEOS doses that will be manufactured in the Company's new fill and finish facility and is expected to be awarded and invoiced during 2021.

November 12, 2020 - Bavarian Nordic A/S announced that Health Canada had expanded the approval of the Company's non-replicating smallpox vaccine, IMVAMUNE®, to include additional indications – specifically, monkeypox and related orthopoxvirus infections and disease in adults 18 years of age and older determined to be at high risk for exposure.

October 1, 2020 - The WHO announced from 1 January through 13 September 2020, a total of 4,594 suspected cases of monkeypox, including 171 deaths (case fatality ratio 3.7%), have been reported in 127 health zones from 17 out of 26 provinces in the Democratic Republic of the Congo.

September 23, 2020 - Phase 3 study: IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo.

April 30, 2020 - Bavarian Nordic A/S announced that the U.S. Biomedical Advanced Research and Development Authority had placed a new order under the contract, awarded in 2017, for the manufacturing and supply of JYNNEOS® at a total value of U.S. $202 million. This new order is also the option to manufacture approximately 13 million freeze-dried doses worth USD 299 million. The Company expects to start manufacturing in 2022, and revenue is recognized following approval by the U.S. FDA of this vaccine formulation.

September 30, 2019 - "In addition to its public health importance, this vaccine will have a direct impact on improving force health protection for U.S. service members who are required to be immunized against smallpox," said Col. E. Darrin Cox, commander of the U.S. Army Medical Research Institute of Infectious Diseases. The USAMRIID-led Phase 3 clinical trial was funded in full by a Cooperative Research and Development Agreement with Bavarian Nordic.

September 24, 2019 - The U.S. Food and Drug Administration announced the approval of Jynneos Smallpox and Monkeypox Vaccine, Live, Non-Replicating, to prevent smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection. This is the only currently FDA-approved vaccine for the prevention of monkeypox disease. Summary Basis for Regulatory Action.

JYNNEOS Smallpox Vaccine Clinical Trial

The FDA approval of JYNNEOS for smallpox comes from a development program comprising 22 clinical trials, including two phase III trials. The program enrolled a total of 7,871 individuals aged between 18 and 80 years who received at least one dose of the vaccine. Approval for monkeypox indication comes from survival data gathered from studies conducted in non-human primates. The survival rate ranged from 80%-100% in animals vaccinated with JYNNEOS, compared to 0%-40% in the control group.

Upon successful completion of the current study, expected in 2021, the Company plans to submit a supplement to the BLA to extend the approval for both formulations of MVA-BN, anticipated in 2022.